



**ESME**  
**Lung Cancer**  
**Publications**

Health Data & Partnerships Department

2024

## Publications 2021

---

1. A real-world study of patients with advanced non-squamous non-small cell lung cancer with EGFR exon 20 insertion: clinical characteristics and outcomes  
Chouaid C, Filleron T, Debieuvre D, Pérol M, Girard N, Dansin E, Léna H, Gervais R, Cousin S, Otto J, Schott R, Planchard D, Madroszyk A, Kaderbhai C, Dubray-Longeras P, Huret S, Pichon E, Clément-Duchêne C, Chenuc G, Simon G, Bosquet L, Quantin X  
Targeted Oncol. 2021 Nov;16(6):801-11 <https://doi.org/10.1007/s11523-021-00848-9>
2. Treatment strategies for unresectable locally advanced non-small cell lung cancer in the real-life ESME cohort  
Girard N, Pérol M, Simon G, Audigier-Valette C, Gervais R, Debieuvre D, Schott R, Quantin X, Coudert B, Lena H, carton M, Robain M, Filleron T, Cpouaid C  
Lung Cancer. 2021 Dec;62:119-27 <https://doi.org/10.1016/j.lungcan.2021.10.017>
3. Biomarker testing in older patients treated for an Advanced or Metastatic Non-squamous Non-Small-Cell Lung Cancer: the French ESME real-life multicenter cohort experience  
Lamy T, Cabarrou B, Planchard D, Quantin X, Schneider S, Binguier M, Besse B, Girard N, Chouaid C, Filleron T, Simon G, Baldini C  
Cancers. 2021 Dec;14(1):92 <https://doi.org/10.3390/cancers14010092>

## Publications 2022

---

4. Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and Germany  
Griesinger F, Pérol M, Girard N, Durand-Zaleski I, Zacharias S, Bosquet L, Janicke M, Quantin X, Groth A, Fleitz A, Cajella A, Patel S, Lacoïn L, Daumont MJ, Penrold JR, Carroll R, Waldenberger D, Reynaud D, Thomas M, Chouaid C.  
Lung cancer. 2022 Oct;172:65-74 <https://doi.org/10.1016/j.lungcan.2022.08.001>
  
5. Effectiveness of nivolumab in patients with advanced non-small cell lung cancer in real-life practice in France and Germany: analysis of the ESME-AMLC and CRISP cohorts  
Chouaid C, Thomas M, Debieuvre D, Durand-Zaleski I, Zacharias S, Bosquet L, Groth A, Fleitz A, Calleja A, Patel S, Lacoïn L, Dauont MJ, Penrod JR, Carroll R, Waldenberg D, Cotté FE, Audigier-Valette C, Griesinger F  
Cancers. 2022 Dec;14(24):6148 <https://www.mdpi.com/2072-6694/14/24/6148#>
  
6. Enrolment of older adults with advanced or metastatic non-small cell lung cancer in first-line clinical trials in the multicentre ESME cohort  
Bringuier M, Carton M, Debieuvre D, Pasquier D, Pérol M, Filleron T, Léna H, Quantin X, Simon S, Baldini C  
J Geriatric Oncol. 2023 Mar;14(2) <https://doi.org/10.1016/j.jgo.2022.101423>

## Publications 2023 (1/2)

---

7. An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations  
Chouaid C, Bosquet L, Girard N, Kron A, Scheffer M, Griesinger F, Sebastian M, Trigo J, Viteri S, Rodrigues B, Rahhali N, Cabrieto J, Diels J, Perualila NJ, Schioppa CA, Sermo, J, Toueg R, Erdmann N, Mielke J, Nematian-Samani M, Martin-Fernandez C, Pfaira I, Li T, Mahadevia P, Wolf J  
Adv Ther. 2023 Jan <https://link.springer.com/article/10.1007/s12325-022-02408-7>
8. Treatment patterns and clinical outcomes of extensive stage small cell lung cancer (SCLC) in the real-world evidence ESME cohort before the era of immunotherapy  
Audigier-Valette C, Filleron T, Debieuvre D, Léna H, Pérol M, Chouaid C, Simon G, Quantin X, Girard N  
Resp Med Res. 2023 Mar;84:101012 <https://doi.org/10.1016/j.resmer.2023.101012>
9. Survival outcomes of patients with metastatic Non-Small Cell Lung Cancer receiving chemotherapy or immunotherapy as first-line in a real-life setting  
Belaroussi Y, Bouteiller F, Bellera C, Pasquier D, Pérol M, Debieuvre D, Filleron T, Girard N, Schott R, Mathoulin-Pellissier S, Martin AL, Cousin S  
*Scientific Reports* 2023 Jun;13(1):9584 <https://doi.org/10.1038/s41598-023-36623-1>

10. Reduced risk of secondary primary extra pulmonary cancer in advanced /metastatic lung cancer patients treated with immune checkpoint inhibitors  
Heudel P, De Monfort A, Debieuvre D, Chouaid C, Carton M, Audigier-Valette C, Fillerin T, Chabaud S, Stancu A, Quantin X, Hiret S, Bosquet L, Blay JY  
Lung Cancer 2023 Jun;182:107280 <https://doi.org/10.1016/j.lungcan.2023.107280>

11. Clinical characteristics and survival outcomes of patients with advanced NSCLC according to KRAS mutational status in the French Real-life ESME cohort  
Thomas QD, Quantin X, Lemercier P, Chouaid C, Schneider S, Filleron T, Remon-Masip J, Pérol M, Debieuvre D, Audigier-Valette C, Justeau G, Loeb A, Hiret S, Clment-Duchene C, Dansin E, Stancu A, Pichon E, Bosquet L, Girard N, Du Rusquec P.  
ESMO Open 2024 <https://doi.org/10.1016/j.esmoop.2024.103473>
  
12. Real-world overview of therapeutic strategies and prognosis of older patients with advanced or metastatic non-small cell lung cancer from the ESME database  
Cabart M, Mourey L, Pasquier D, Schneider S, Lena H, Girard N, Chouaid C, Schott R, Hiret S, Debieuvre D, Quantin X, Madroszyk A, Dubray-Longeras P, Pichon E, Baranzelli A, Justeau G, Pérol M, Bosquet L, Cabarro B.  
J Geriatric Oncol 2024 <https://doi.org/10.1016/j.jgo.2024.101819>
  
13. Optimizing treatment strategies for EGFR-mutated NSCLC treated with osimertinib: real-world outcomes and insights  
Thomas QD, Girard N, Bosquet L, Cavaillon S, Filleron T, Eltaief S, Chouaid C, Lena H, Debieuvre D, Pérol M, Quantin X  
Cancers 2024 <https://doi.org/10.3390/cancers16213563>